Erythema migrans - Causes, Treatment & When to See a Doctor

What is Erythema migrans?

Erythema migrans (EM) is the characteristic skin lesion that appears early in the course of Lyme disease, a bacterial infection transmitted by the bite of infected Ixodes ticks (commonly called deer ticks). The lesion usually starts as a small red bump at the site of the tick bite and expands over days to weeks, often forming a target‑like “bull’s‑eye” pattern. While EM is most strongly associated with Lyme disease, similar expanding rashes can be seen in other infectious or inflammatory conditions.

In most patients, EM is the first sign that the bacteria Borrelia burgdorferi (or related species) have entered the body. Recognizing it promptly can lead to early treatment, which dramatically reduces the risk of long‑term complications such as joint arthritis, neurologic problems, or heart block.

Common Causes

Although erythema migrans is classically linked to Lyme disease, several other conditions can produce a similar expanding rash. Below are the most frequently encountered causes:

• Lyme disease – infection with Borrelia burgdorferi (U.S.) or B. afzelii/B. garinii (Europe/Asia).
• Southern tick‑associated rash illness (STARI) – a rash that follows bites from the lone star tick (Amblyomma americanum). The rash resembles EM but is usually less pronounced.
• Rickettsial infections – such as Rocky Mountain spotted fever, which can produce a maculopapular rash that may expand.
• Babesiosis – a protozoal infection transmitted by the same tick as Lyme; a rash is rare but can coexist with EM.
• Rapidly progressive cellulitis – bacterial skin infection (Staphylococcus or Streptococcus) that can mimic an expanding erythema.
• Cutaneous fungal infections – deep dermatophyte or candidal infections sometimes produce annular lesions.
• Autoimmune conditions – such as granuloma annulare or sarcoidosis, which may generate ring‑shaped plaques.
• Fixed drug eruption – a localized reaction to a medication that can appear as a red, expanding patch.
• Vasculitis – small‑vessel inflammation (e.g., leukocytoclastic vasculitis) can create dusky, expanding plaques.
• Reactive erythema – a nonspecific inflammatory response to trauma or insect bites that enlarges over time.

Associated Symptoms

Erythema migrans rarely appears in isolation. When it is caused by Lyme disease, patients often report one or more of the following systemic signs within days to weeks of the rash:

• Fever, chills, or occasional night sweats.
• Headache – sometimes described as “meningeal” (stiff neck).
• Fatigue or a general feeling of “being unwell.”
• Muscle aches (myalgia) and joint pain, especially in the knees.
• Neck stiffness or facial palsy (Bell’s palsy) – less common in early disease.
• Flu‑like symptoms such as nausea, loss of appetite, or mild abdominal discomfort.
• Neurologic symptoms like tingling or numbness in the extremities (rare in the first few weeks).

In STARI and other tick‑related rashes, the systemic symptoms tend to be milder and may resolve without antibiotics, though a short course of doxycycline is often given as a precaution.

When to See a Doctor

Because early treatment prevents serious complications, you should seek medical care promptly if you notice any of the following:

• A red expanding rash that is >5 cm (about 2 inches) in diameter, especially if it has a central clearing (bull’s‑eye appearance).
• The rash appears after a known or suspected tick bite, even if the bite site is no longer visible.
• You develop fever, headache, neck stiffness, or joint pain together with the rash.
• The lesion is painful, ulcerated, or has blisters.
• You have a history of recent travel to areas where Lyme disease, STARI, or other tick‑borne illnesses are common.
• You are pregnant, immunocompromised, or have pre‑existing heart disease—conditions that raise the risk of severe Lyme complications.

Diagnosis

Diagnosing erythema migrans relies on a combination of clinical observation, patient history, and, in some cases, laboratory testing.

Clinical Evaluation

1. Physical examination – the clinician measures the size, shape, and borders of the rash. Classic EM is >5 cm, expands gradually, and may have central clearing.
2. History of tick exposure – details about outdoor activities, geography, and time of year help assess risk.
3. Symptom review – presence of fever, headache, or joint pain raises suspicion for systemic infection.

Laboratory Tests

• Two‑tier serology – an initial ELISA followed by a Western blot if the ELISA is positive. In early EM (first 2–4 weeks), antibodies may still be negative; a repeat test after 2–4 weeks is recommended if initial testing is done.
• Polymerase chain reaction (PCR) – can detect Borrelia DNA in skin biopsy samples, joint fluid, or cerebrospinal fluid but is not routinely required for early EM.
• Complete blood count (CBC) and metabolic panel – useful for assessing systemic involvement, especially in patients with fever or joint swelling.

When a Biopsy Is Considered

Skin biopsy is rarely needed but may be performed if the lesion looks atypical, if there is concern for skin cancer, or if the diagnosis is uncertain after other causes have been excluded.

Treatment Options

Because EM is an early manifestation of a potentially disseminated infection, the goal of therapy is to eradicate Borrelia quickly and prevent later complications.

Antibiotic Therapy

Regimen	Dosage	Duration	Typical Use
Doxycycline	100 mg orally twice daily	10–21 days	First‑line for adults and children ≥8 years; also covers possible co‑infection with anaplasma or ehrlichia.
Amoxicillin	500 mg orally three times daily	14–21 days	Preferred for pregnant women, infants, or patients who cannot tolerate doxycycline.
Cefuroxime axetil	500 mg orally twice daily	14–21 days	Alternative for patients allergic to doxycycline and amoxicillin.

For patients with severe allergy to all oral agents, a short course of intravenous ceftriaxone (2 g daily) may be used under hospital supervision.

Supportive Care

• Rest and adequate hydration.
• Acetaminophen or ibuprofen for fever and musculoskeletal pain (unless contraindicated).
• Topical soothing agents (e.g., calamine lotion) if the rash is itchy, though most patients find relief as the lesion resolves.

Follow‑Up

Most patients improve within 24–48 hours of starting antibiotics, and the rash fades over 2–4 weeks. A follow‑up visit (usually 2–4 weeks later) confirms resolution and checks for lingering symptoms such as joint swelling or neurologic changes.

Prevention Tips

Because EM is almost always a tick‑borne phenomenon, reducing tick exposure is the most effective preventive strategy.

• Dress appropriately when hiking or working in wooded/brushy areas – wear long sleeves, long pants, and tuck pants into socks.
• Use EPA‑registered insect repellents containing DEET (30‑50 %), picaridin, or IR3535 on skin; treat clothing with permethrin.
• Perform tick checks every 2 hours while outdoors and again within 24 hours after returning home. Promptly remove attached ticks with fine‑tipped tweezers.
• Maintain your yard – keep grass trimmed, remove leaf litter, and create a 3‑foot barrier of wood chips between forested areas and play zones.
• Consider prophylactic antibiotics for high‑risk bites: a single 200 mg dose of doxycycline within 72 hours of removal is recommended by the CDC for bites in endemic areas when the tick has been attached ≥36 hours.
• Vaccination status – there is currently no licensed Lyme vaccine for humans in the U.S., but research is ongoing. Stay informed about any new recommendations.

Emergency Warning Signs

Key Take‑Home Points

• Erythema migrans is the hallmark skin lesion of early Lyme disease; it appears 3‑30 days after a tick bite.
• Prompt recognition and treatment with doxycycline or an alternative antibiotic usually cures the infection and prevents late complications.
• Even if the rash is mild, any suspected tick exposure warrants a medical evaluation, especially if systemic symptoms are present.
• Preventive measures—proper clothing, repellents, and thorough tick checks—are the most reliable way to avoid EM and Lyme disease.

For the most up‑to‑date guidance, consult reputable sources such as the CDC, Mayo Clinic, and the NIH.